The influence of FDG PET-CT on the detection of extrahepatic disease in patients being considered for resection of colorectal liver metastasis

Annals of the Royal College of Surgeons of England

Volumn 96, Issue 3, 2014, Pages 211-215

  Lake, E S ^a   Wadhwani, S ^a   Subar, D ^a   Kauser, A ^a   Harris, C ^a   Chang, D ^a   Lapsia, Snehal ^a  

^a EAST LANCASHIRE HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Colorectal cancer; Hepatectomy; Liver neoplasm; Positron emission tomography

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LIVER TUMOR; MALE; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTIMODAL IMAGING; POSITRON EMISSION TOMOGRAPHY; PRECANCER; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PRECANCEROUS CONDITIONS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84897936434     PISSN: 00358843     EISSN: None     Source Type: Journal    
DOI: 10.1308/003588414X13814021679195     Document Type: Article

References (22)

1. Bowel Cancer. NHS Choices. http://www.nhs.uk/Conditions/Cancer-of-the-colonrectum- or-bowel/ (cited January 2014).
2. Rees M, Tekkis PP, Welsh FK et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 2008; 247: 125-135.
3. Simmonds PC, Primrose JN, Colquitt JL et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006; 94: 982-999.
4. Hughes KS, Simon R, Songhorabodi S et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery 1986; 100: 278-284.
5. Wiering B, Ruers TJ, Krabbe PF et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann Surg Oncol 2007; 14: 818-826.
6. Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis-meta-analysis. Radiology 2005; 237: 123-131.
7. Mainenti P, Mancini M, Mainolfi et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010; 35: 511-521.
8. Bhattacharjya S, Bhattacharjya T, Baber S et al. Prospective study of contrastenhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 2004; 91: 1,361-1,369.
9. Rappeport ED, Loft A, Berthelsen AK et al. Contrast-enhanced FDG-PET/CT vs SPIO-enhanced MRI vs FDG-PET vs CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 2007; 48: 369-378.
10. Floriani I, Torri V, Rulli E et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and metaanalysis. J Magn Reson Imaging 2010; 31: 19-31.
11. National Institute for Health and Clinical Excellence. Colorectal Cancer: The Diagnosis and Management of Colorectal Cancer. London: NICE; 2011. p93.
12. Wiering B, Krabbe PF, Jager GJ et al. The impact of fluor-18-deoxyglucosepositron emission tomography in the management of colorectal liver metastases. Cancer 2005; 104: 2,658-2,670.
13. Selzner M, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240: 1,027-1,034.
14. Royal College of Radiologists. Recommendations for Cross-Sectional Imaging in Cancer Management. London: RCR; 2006.
15. Briggs RH, Chowdhury FU, Lodge JP, Scarsbrook AF. Clinical impact of FDG PET-CT in patients with potentially operable metastatic colorectal cancer. Clin Radiol 2011; 66: 1,167-1,174.
16. Engledow AH, Skipworth JR, Pakzad F et al. The role of 18FDG PET/CT in the management of colorectal liver metastases. HPB 2012; 14: 20-25.
17. Truant S, Huglo D, Hebbar M et al. Prospective evaluation of the impact of [18F]fluoro-2-deoxy-D-glucose positron emission tomography of resectable colorectal liver metastases. Br J Surg 2005; 92: 362-369.
18. Fernandez FG, Drebin JA, Linehan DC et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004; 240: 438-447.
19. Strasberg SM, Dehdashti F, Siegel BA et al. Survival of patients evaluated by FDG-PET before hepatic resection for metastatic colorectal carcinoma: a prospective database study. Ann Surg 2001; 233: 293-299.
20. Kong G, Jackson C, Koh DM et al. The use of 18F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 2008; 35: 1,323-1,329.
21. PET Scan. NHS Choices. http://www.nhs.uk/Conditions/PET-scan/ (cited January 2014).
22. Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318.